3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Gynecologic
1
Breast
1
Conditions
Breast Neoplasms
37
Neoplasm Metastasis
6
Neoplasms by Site
2
Neoplasms
2
Hereditary Sensory and Autonomic Neuropathies
2
Endometrial Neoplasms
2
Colorectal Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Breast Diseases
2
Anatomic Stage II Breast Cancer AJCC v8
2
Uterine Cervical Neoplasms
1
Unilateral Breast Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Solid Tumors
1
Sarcoma
1
Recurrence
1
Prostatic Neoplasms
1
Ovarian Neoplasms
1
Melanoma
1
Lung Neoplasms
1
Locoregional Recurrence
1
Locally Advanced (Inoperable) or Metastatic Breast Cancer
1
Liposarcoma
1
Leiomyosarcoma
1
Head and Neck Neoplasms
1
HR+/HER2- Breast Cancer
1
HER2 Negative Breast Cancer Not Immediately Operated
1
HER2 Negative Breast Cancer
1
Glioma
1
Glioblastoma
1
Interventions
Bevacizumab
35
Paclitaxel
31
Carboplatin
24
pembrolizumab
23
Specimen Handling
21
Magnetic Resonance Spectroscopy
19
Gemcitabine
18
olaparib
16
liposomal doxorubicin
16
Cyclophosphamide
15
fludarabine
12
Topotecan
12
Biopsy
12
niraparib
11
Cisplatin
10
Taxes
8
Nivolumab
8
Immunoglobulin G
8
Fulvestrant
8
Disulfides
8
Doxorubicin
7
aldesleukin
6
Surveys and Questionnaires
6
palbociclib
5
Oxaliplatin
5
Fluorouracil
5
trastuzumab deruxtecan
4
oregovomab
4
mirvetuximab soravtansine
4
X-Rays
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Ovarian Neoplasms
×
ribociclib
×
90 days
×
Clear all
NCT05768139
2026-06-04
PIKALO-1
Eli Lilly and Company
Phase 1/2
Recruiting
880 enrolled